

SURMODICS INC  
Form 10-Q  
May 09, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D. C. 20549  
FORM 10-Q**

**(Mark One)**

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2008**

**or**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission File Number: 0-23837**

**SurModics, Inc.**

(Exact name of registrant as specified in its Charter)

MINNESOTA

(State of incorporation)

41-1356149

(I.R.S. Employer Identification No.)

9924 West 74<sup>th</sup> Street

Eden Prairie, Minnesota 55344

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (952) 829-2700

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2).

Yes  No

The number of shares of the registrant's common stock, \$.05 par value per share, outstanding as of April 30, 2008 was 18,279,553.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Item 4. Controls and Procedures

PART II OTHER INFORMATION

Item 1. Legal Proceedings

Item 1A. Risk Factors

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Item 3. Defaults Upon Senior Securities

Item 4. Submission of Matters to a Vote of Security Holders

Item 5. Other Information

Item 6. Exhibits

SIGNATURES

EXHIBIT INDEX

Real Estate Purchase Agreement

302 Certification of Chief Executive Officer

302 Certification of Chief Financial Officer

906 Certification of Chief Executive Officer

906 Certification of Chief Financial Officer

---

**Table of Contents****PART I. FINANCIAL INFORMATION**

## Item 1. Financial Statements

**SurModics, Inc. and Subsidiaries**  
 Condensed Consolidated Balance Sheets  
 (unaudited)

<i>(In thousands, except share data)</i>	<b>March 31, 2008</b>	<b>September 30, 2007</b>
<b>ASSETS</b>		
Current assets		
Cash and cash equivalents	\$ 26,746	\$ 13,812
Short-term investments	11,083	12,496
Accounts receivable, net of allowance for doubtful accounts of \$40 as of March 31, 2008 and September 30, 2007	17,821	16,138
Inventories	2,591	2,497
Deferred tax asset	1,116	1,116
Income taxes receivable	3,814	
Prepays and other	1,424	1,836
 Total current assets	 64,595	 47,895
Property and equipment, net	20,934	19,738
Restricted cash	1,630	
Long-term investments	43,089	43,917
Deferred tax asset	8,597	5,908
Intangible assets, net	16,983	18,399
Goodwill	18,298	15,686
Other assets	10,911	19,788
 Total assets	 \$ 185,037	 \$ 171,331
 <b>LIABILITIES AND STOCKHOLDERS EQUITY</b>		
Current liabilities		
Accounts payable	\$ 4,216	\$ 2,541
Accrued liabilities	3,394	4,187
Accrued income taxes payable		6,227
Deferred revenue	3,911	5,586
Other current liabilities	4,451	1,311
 Total current liabilities	 15,972	 19,852
Deferred revenue, less current portion	24,203	20,305
Other long-term liabilities	1,597	252
 Total liabilities	 41,772	 40,409
 Stockholders Equity		

Edgar Filing: SURMODICS INC - Form 10-Q

Series A preferred stock \$0.05 par value, 450,000 shares authorized; no shares issued and outstanding		
Common stock \$0.05 par value, 45,000,000 shares authorized; 18,233,618 and 18,164,980 shares issued and outstanding	912	909
Additional paid-in capital	79,863	76,670
Accumulated other comprehensive income	37	1,723
Retained earnings	62,453	51,620
Total stockholders equity	143,265	130,922
Total liabilities and stockholders equity	\$ 185,037	\$ 171,331

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Table of Contents**

**SurModics, Inc. and Subsidiaries**  
Condensed Consolidated Statements of Income  
(unaudited)

<i>(In thousands, except per share data)</i>	Three Months Ended March 31,		Six Months Ended March 31,	
	2008	2007	2008	2007
Revenue				
Royalties and license fees	\$ 13,809	\$ 13,028	\$ 26,987	\$ 26,247
Product sales	4,700	3,381	9,907	6,107
Research and development	7,198	953	12,642	1,748
Total revenue	25,707	17,362	49,536	34,102
Operating costs and expenses				
Product costs	2,154	1,092	4,129	2,179
Research and development	10,370	5,717	19,904	10,924
Selling, general and administrative	6,002	2,468	10,751	4,805
Total operating costs and expenses	18,526	9,277	34,784	17,908
Income from operations	7,181	8,085	14,752	16,194
Other income				
Investment income	1,051	1,187	2,004	2,520
Other income (loss)	133	(15)	900	(19)
Other income	1,184	1,172	2,904	2,501
Income before income taxes	8,365	9,257	17,656	18,695
Income tax provision	(3,258)	(3,582)	(6,903)	(7,029)
Net income	\$ 5,107	\$ 5,675	\$ 10,753	\$ 11,666
Basic net income per share	\$ 0.28	\$ 0.31	\$ 0.60	\$ 0.64
Diluted net income per share	\$ 0.28	\$ 0.31	\$ 0.58	\$ 0.64
Weighted average shares outstanding				
Basic	18,102	18,017	18,055	18,232
Dilutive effect of outstanding stock options	326	116	366	110
Diluted	18,428	18,133	18,421	18,342

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Table of Contents**

**SurModics, Inc. and Subsidiaries**  
Condensed Consolidated Statements of Cash Flows  
(unaudited)

<i>(In thousands)</i>	Six Months Ended March 31,	
	2008	2007
<b>Operating Activities:</b>		
Net income	\$ 10,753	\$ 11,666
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	2,993	1,960
(Gain) loss on equity method investment and sales of investments	(857)	19
Amortization of premium (discount) on investments	2	(993)
Stock-based compensation	5,351	2,870
Deferred taxes	(1,129)	(102)
Excess tax benefits from exercise of stock options	(765)	
Loss on disposals of property and equipment	22	7
Change in operating assets and liabilities:		
Accounts receivable	(1,683)	4,613
Inventories	(94)	(38)
Accounts payable and accrued liabilities	31	(1,102)
Income taxes	(7,603)	(2,349)
Deferred revenue	1,988	375
Prepays and other	(65)	(472)
<b>Net cash provided by operating activities</b>	<b>8,944</b>	<b>16,454</b>
<b>Investing Activities:</b>		
Purchases of property and equipment	(2,056)	(1,610)
Proceeds from sales of property and equipment	26	
Purchases of available-for-sale investments	(7,810)	(63,211)
Sales/maturities of available-for-sale investments	16,215	85,707
Purchases of held-to-maturity investments	(4,333)	
Purchase of licenses and patents	(65)	(68)
Investment in other strategic assets		(2,117)
Collection of notes receivable	5,870	261
Cash restricted for land purchase	(1,630)	
Other investing activities	(567)	
<b>Net cash provided by investing activities</b>	<b>5,650</b>	<b>18,962</b>
<b>Financing Activities:</b>		
Excess tax benefits from exercise of stock options	765	
Issuance of common stock	1,848	1,885
Repurchase of common stock	(2,601)	(35,030)
Purchase of common stock to fund employee taxes	(1,450)	
Repayment of notes payable	(222)	

Edgar Filing: SURMODICS INC - Form 10-Q

Net cash used in financing activities	(1,660))	(33,145)
Net change in cash and cash equivalents	12,934	2,271
Cash and cash equivalents		
Beginning of period	13,812	3,751
End of period	\$ 26,746	\$ 6,022
Supplemental Information		
Cash paid for income taxes	\$ 15,381	\$ 9,468
Noncash transaction accrued earnout payments in connection with business		
acquisition agreements	\$ 3,148	\$
Noncash transaction acquisition of property, plant, and equipment on account	\$ 953	\$ 118

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Table of Contents**

**SurModics, Inc. and Subsidiaries**  
**Notes to Condensed Consolidated Financial Statements**  
**Period Ended March 31, 2008**  
**(Unaudited)**

**(1) Basis of Presentation**

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and reflect all adjustments, consisting solely of normal recurring adjustments, needed to fairly present the financial results for the periods presented. These financial statements include some amounts that are based on management's best estimates and judgments. These estimates may be adjusted as more information becomes available, and any adjustment could be significant. The impact of any change in estimates is included in the determination of earnings in the period in which the change in estimate is identified. The results of operations for the three-month and six-month periods ended March 31, 2008 are not necessarily indicative of the results that may be expected for the entire 2008 fiscal year.

The six-month period ended March 31, 2008 includes a reclassification of \$807,000 of research and development expenses reported as product costs in the first quarter. The expenses reclassified were out-of-pocket project costs related to research and development activities.

In July 2007, the Company acquired Brookwood Pharmaceuticals, Inc., from Southern Research Institute, for \$40 million in cash at closing and up to an additional \$22 million in cash upon the successful achievement of specified milestones. In the second quarter of fiscal 2008 a milestone was achieved and \$2 million of additional purchase price was recorded as an increase to goodwill. Brookwood specializes in proprietary injectable microparticles and implants to provide sustained delivery of drugs being developed by leading pharmaceutical, biotechnology and medical device clients as well as emerging companies. This acquisition is helping the Company broaden its technology offerings to customers, diversifying the range of markets in which the Company participates, expanding the Company's customer base, and enhancing the pipeline of potential revenue generating opportunities.

In August 2007, the Company acquired BioFX Laboratories, Inc., a provider of substrates to the *in vitro* diagnostics industry, for \$11.3 million in cash at closing and up to an additional \$11.4 million in cash upon the successful achievement of specified revenue targets. In the first quarter of fiscal 2008 a milestone was achieved and \$1.1 million of additional purchase price was recorded as an increase to goodwill. BioFX is a leading manufacturer of substrates, a critical component of diagnostic test kits used to detect and signal that a certain reaction has taken place. The acquisition of BioFX is broadening the Company's product portfolio in the *in vitro* diagnostics market.

The operating results for the Brookwood Pharmaceuticals, Inc. and BioFX Laboratories, Inc. businesses are included in the consolidated results of operations from the dates of acquisition.

In accordance with the rules and regulations of the United States Securities and Exchange Commission, the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited consolidated financial statements of the Company. These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the year ended September 30, 2007, and footnotes thereto included in the Company's Form 10-K as filed with the United States Securities and Exchange Commission on December 14, 2007.

**(2) New Accounting Pronouncements**

In September 2006, the Financial Accounting Standards Board ( FASB ) issued Statement of Financial Accounting Standards ( SFAS ) No. 157, *Fair Value Measurements* ( SFAS No. 157 ). This statement establishes a framework for measuring fair value and requires enhanced disclosures about fair value measurements. SFAS No. 157 applies to fair value measurements required by existing accounting pronouncements and does not require any new fair value measurements. SFAS No. 157 is effective for the Company in fiscal 2009. FASB Staff Position No. FAS 157-2 provides a deferral of SFAS No. 157 provisions for non-financial assets and liabilities until fiscal 2010. The Company has not determined the impact, if any, the adoption of this statement will have on its consolidated financial statements.

In February 2007, the FASB issued SFAS No. 159, *The Fair Value Option for Financial Assets and Financial Liabilities* ( SFAS No. 159 ). SFAS No. 159 permits entities to choose to measure many financial assets and financial liabilities at fair value. Unrealized gains and losses on items for which the fair value option has been elected will be

reported in earnings. SFAS No. 159 is effective for the Company in fiscal 2009. The Company is currently evaluating the impact of SFAS No. 159 on its consolidated financial statements.

In December 2007, the FASB issued SFAS No. 141(R), *Business Combinations* ( SFAS No. 141(R) ), which establishes principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, and any noncontrolling interest in an acquiree, including the recognition and measurement of goodwill acquired in a business combination. SFAS No. 141(R) is effective for the Company in fiscal 2010. Earlier adoption is prohibited and once adopted SFAS No. 141(R) will impact recognition and measurement of future business combinations.

**Table of Contents****(3) Inventories**

Inventories are principally stated at the lower of cost or market using the specific identification method and include direct labor, materials and overhead. Inventories consisted of the following components (*in thousands*) :

	<b>March 31, 2008</b>	<b>September 30, 2007</b>
Raw materials	\$ 1,129	\$ 1,241
Finished products	1,462	1,256
Total	\$ 2,591	\$ 2,497

**(4) Restricted Cash**

The Company has entered into an agreement to purchase an undeveloped parcel of land, as described in Note 12. To secure the performance of its obligations under the purchase agreement, the Company delivered a standby letter of credit in the amount of \$1.6 million. This letter of credit is fully collateralized by restricted cash that the Company deposited with the issuing institution.

**(5) Other Assets**

Other assets consist principally of strategic investments. The Company accounts for its strategic investments under the cost method, except for its investments in Paragon Intellectual Properties, LLC ( Paragon ), Paragon s subsidiary, Apollo Therapeutics, LLC, and Brookwood s investment in Aeon Bioscience, Inc. (included in the Other category in the table below), which are accounted for under the equity method. Other assets consisted of the following (*in thousands*):

	<b>March 31, 2008</b>	<b>September 30, 2007</b>
Investment in OctoPlus	\$ 5,506	\$ 8,762
Long-term portion of note receivable		5,158
Investment in Paragon and subsidiary	3,242	3,632
Investment in ThermopeutiX	1,185	1,185
Investment in Novocell	559	559
Other	419	492
Total other assets	\$ 10,911	\$ 19,788

In September 2005, the Company entered into an agreement to sell a contract manufacturing facility and 27 acres of land located in Bloomington, Minnesota. The terms of the sale agreement included a \$100,000 cash down payment and a note receivable of \$6.9 million, which was collateralized by the property. The terms of the note called for monthly installment payments of principal and interest at 6% with the remaining amount due and payable in September 2010. On January 14, 2008, the outstanding balance (including principal and accrued interest) of \$5.8 million was repaid in its entirety.

The Company recognized revenue of \$1.5 million and \$76,000 for the three-month period ended March 31, 2008 and 2007, respectively, and recognized revenue of \$2.4 million and \$125,000 for the six-month period ended March 31, 2008 and 2007, respectively, from activity with companies in which it had a strategic investment.

**(6) Intangible Assets**

Intangible assets consist principally of acquired patents and technology, customer relationships, licenses, and trademarks. The Company recorded amortization expense of \$741,000, and \$447,000 for the three months ended March 31, 2008 and 2007, respectively. The Company recorded amortization expense of \$1,481,000, and \$532,000 for the six months ended March 31, 2008 and 2007, respectively.

In September 2004, the Company made a commitment to purchase for \$7.0 million certain additional sublicense rights and the accompanying future royalty revenue streams under certain sublicenses through an amendment to the Company's diagnostic format patent license with Abbott Laboratories. Prior to such amendment, the Company was receiving only a

**Table of Contents**

portion of the royalties under such sublicenses. The first \$5.0 million installment was paid in fiscal 2005, and an additional \$1.0 million installment was paid in fiscal 2007. The remaining \$1.0 million installment is reflected in other current liabilities.

Intangible assets consisted of the following (*in thousands*):

	Useful life (in years)	March 31, 2008	September 30, 2007
Customer list	9 11	\$ 7,340	\$ 7,340
Abbott license	4	7,037	7,037
Core technology	8 18	6,930	6,933
Patents and other	7 20	2,056	1,988
Trademarks		580	580
Less accumulated amortization of intangible assets		(6,960)	(5,479)
Intangible assets, net		\$ 16,983	\$ 18,399

Based on the intangible assets in service as of March 31, 2008, estimated amortization expense for each of the next five years ending March 31 is as follows (*in thousands*):

2009	\$2,550
2010	1,299
2011	1,299
2012	1,299
2013	1,299

**(7) Stock-based Compensation**

The Company's stock-based compensation expenses were as follows (*in thousands*):

	Three months ended March 31,		Six months ended March 31,	
	2008	2007	2008	2007
Product costs	\$ 63	\$ 25	\$ 87	\$ 52
Research and development	1,039	714	1,876	1,407
Selling, general and administrative	2,296	719	3,388	1,411
Total	\$ 3,398	\$ 1,458	\$ 5,351	\$ 2,870

As of March 31, 2008, approximately \$15.1 million of total unrecognized compensation costs related to non-vested awards is expected to be recognized over a weighted average period of approximately 2.5 years.

**Stock Option Plans**

The Company accounts for stock-based compensation in accordance with SFAS No. 123(R), *Share Based Payment* ( SFAS 123(R) ), which requires all share-based payments, including grants of stock options, to be recognized in the income statement as an operating expense, based on their fair values, over the requisite service period.

**Table of Contents**

The Company uses the Black-Scholes option pricing model to determine the weighted average fair value of options. The weighted average fair values of options granted during the three-month periods ended March 31, 2008 and 2007 were \$22.21 and \$14.54, respectively. The weighted average fair values of options granted during the six-month periods ended March 31, 2008 and 2007 were \$25.19 and \$16.56, respectively. The assumptions used as inputs in the model were as follows:

	Three months ended March 31,		Six months ended March 31,	
	2008	2007	2008	2007
Risk-free interest rates	3.0%	4.8%	3.6%	4.7%
Expected life (years)	6.2	4.9	6.5	5.8
Expected volatility	44.6%	42.5%	47.8%	49.4%
Dividend yield	0%	0%	0%	0%

The risk-free interest rate assumption was based on yields for U.S. Treasury bonds with maturities similar to those of the expected term of the award. The expected life of options granted is determined based on the Company's experience. Expected volatility is based on the Company's stock price movement over a period approximating the expected term. Based on management's judgment, dividend rates are expected to be zero for the expected life of the options. The Company also estimates forfeitures of options granted, which is based on historical experience.

The Company's Incentive Stock Options ( ISO ) are granted at a price of at least 100% of the fair market value of the common stock of the Company ( Common Stock ) on the date of the grant or 110% with respect to optionees who own more than 10% of the total combined voting power of all classes of stock. ISO's expire in seven years or upon termination of employment and are exercisable at a rate of 20% per year commencing one year after the date of grant. Nonqualified stock options ( NQSO ) are granted at fair market value on the date of grant. NQSO's expire in 7 to 10 years and are exercisable at rates of 20% per year from the date of grant, or 20% to 33% per year commencing one year after the date of grant.

*Restricted Stock Awards*

The Company has entered into restricted stock agreements with certain key employees, covering the issuance of Common Stock ( Restricted Stock ). Under SFAS No.123(R), these shares are considered to be non-vested shares. The Restricted Stock will be released to the key employees if they are employed by the Company at the end of the vesting period. The stock-based compensation table above includes Restricted Stock expenses of \$749,000 and \$1,206,000 for the three-month and six-month periods ended March 31, 2008, respectively, and \$287,000 and \$556,000 for the three-month and six-month periods ended March 31, 2007, respectively.

*Performance Share Awards*

Historically, the Company has entered into performance share agreements with certain key employees, covering the issuance of Common Stock ( Performance Shares ). The Performance Shares vest upon the achievement of certain performance objectives, which must be achieved during the performance period. Compensation is recognized in each period based on management's best estimate of the achievement level of the grants' specified performance objectives and the resulting vesting amounts. For the three-month and six-month periods ended March 31, 2008, the Company recognized \$308,000 associated with the fair value of vesting of grants. For the three-month and six-month periods ended March 31, 2007, the Company recognized \$380,000 and \$138,000 of the fair value of anticipated vesting of grants, respectively. The stock-based compensation table above includes the Performance Share expenses.

*1999 Employee Stock Purchase Plan*

Under the 1999 Employee Stock Purchase Plan ( Stock Purchase Plan ), the Company is authorized to issue up to 200,000 shares of common stock. All full-time and part-time employees can choose to have up to 10% of their annual compensation withheld to purchase the Company's common stock at purchase prices that are 85% of the average closing price as defined in the Stock Purchase Plan. As of March 31, 2008 and 2007, there were \$57,000 and \$48,000 of employee contributions, respectively, included in accrued liabilities in the accompanying condensed consolidated balance sheets. Stock compensation expense recognized related to the Stock Purchase Plan for three-month periods ended March 31, 2008 and 2007 totaled \$45,000 and \$39,000, respectively. Stock compensation expense recognized

related to the Stock Purchase Plan for the six-month periods ended March 31, 2008 and 2007 totaled \$83,000 and \$79,000, respectively. The stock-based compensation table above includes the Stock Purchase Plan expenses.

**Table of Contents****(8) Comprehensive Income**

The components of comprehensive income are as follows (*in thousands*):

	Three months ended		Six months ended	
	March 31,		March 31,	
	2008	2007	2008	2007
Net income	\$ 5,107	\$ 5,675	\$ 10,754	\$ 11,666
Other comprehensive income:				
Unrealized holding gains (losses) on available-for-sale securities arising during the period, net of tax	(671)	1,041	(882)	2,841
Adjustment for realized (gains) losses included in net income, net of tax	(241)	9	(804)	12
Comprehensive income	\$ 4,195	\$ 6,725	\$ 9,068	\$ 14,519

**(9) Income Taxes**

The Company adopted the provisions of FASB Interpretation No. 48 ( FIN 48 ) *Accounting for Uncertainty in Income Taxes - An Interpretation of FASB Statement No. 109*, on October 1, 2007. Upon adoption of FIN 48, the Company recorded a net \$79,000 benefit related to taxes, which was recorded as an increase to the October 1, 2007 beginning retained earnings balance. As of the adoption date, the Company has gross unrecognized tax benefits of \$1.1 million and if recognized, this total amount would impact the effective tax rate. The Company has classified \$160,000 of the gross unrecognized tax benefits as a current liability, reflecting the amount the Company expects to pay during the next twelve months in connection with certain amended tax returns filed by the Company. The remaining liability for unrecognized tax benefits has been classified as non-current, as no payments are expected to be made in the next twelve months. The Company does not anticipate any other significant increases or decreases in unrecognized tax benefits within twelve months of adoption of FIN 48. Interest and penalties related to unrecognized tax benefits are recorded in income tax expense. As of October 1, 2007, a gross balance of \$445,000 of interest and penalties has been accrued related to the unrecognized tax benefits balance.

The Company files tax returns, including returns for its subsidiaries, in the United States federal jurisdiction and in various state jurisdictions. Uncertain tax positions are related to tax years that remain subject to examination. As of the date of the adoption, U.S. tax returns for fiscal years ended September 30, 2005, 2006, and 2007 remain subject to examination by federal tax authorities. Tax returns for state and local jurisdictions for fiscal years ended September 30, 2003 through 2007 remain subject to examination by state and local tax authorities.

**(10) Operating Segments**

Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance.

SurModics manages its business on the basis of the operating segments noted in the table below, which are comprised of the Company's seven business units. The three operating segments are aggregated into one reportable segment. The Drug Delivery operating segment contains: (1) the Drug Delivery business unit, which is responsible for technologies dedicated to site specific delivery of drugs; (2) the Ophthalmology business unit, which is dedicated to the advancement of treatments for eye diseases, such as age-related macular degeneration (AMD) and diabetic macular edema (DME), two of the leading causes of blindness; and (3) the Brookwood Pharmaceuticals unit, which provides proprietary polymer-based technologies to companies developing improved pharmaceutical products. The Hydrophilic and Other operating segment consists of three business units: (1) the Hydrophilic Technologies business unit, which focuses on enhancing medical devices with advanced lubricious coatings that facilitate their placement and maneuverability in the body; (2) the Regenerative Technologies business unit, which is developing platforms intended to augment or replace tissue/organ function (e.g., cell encapsulation applications), or to modify medical devices to facilitate tissue/organ recovery through natural repair mechanisms (e.g., hemo/biocompatible or prohealing

coatings); and (3) the Orthopedics business unit, which is committed to innovative solutions for orthopedics patients using proven SurModics technologies, and creating new technology solutions to existing patient care gaps in the orthopedics field. The In Vitro operating segment contains the In Vitro Technologies (formerly Diagnostics and Drug Discovery) business unit, which includes the Company's genomics slide technologies, stabilization products, antigens and substrates for immunoassay diagnostics tests, its *in vitro* diagnostic format technology and its synthetic ECM cell culture products.

**Table of Contents**

Each operating segment has similar economic characteristics, technology, manufacturing processes, customers, regulatory environments, and shared infrastructures. The Company manages its expenses on a company-wide basis, as many costs and activities are shared among the business units. The focus of the business units is providing solutions to customers and maximizing financial performance over the long term. The accounting policies for segment reporting are the same as for the Company as a whole. The table below presents revenue from the three operating segments for the three-month and six-month periods in fiscal 2008 and 2007, respectively (*in thousands*):

	Three months ended		Six months ended	
	March 31,		March 31,	
	2008	2007	2008	2007
Operating segment:				
Drug Delivery	\$ 11,955	\$ 6,205	\$ 22,723	\$ 12,834
Hydrophilic and Other	8,261	6,546	15,815	11,823
In Vitro	5,491	4,611	10,998	9,445
Total revenue	\$ 25,707	\$ 17,362	\$ 49,536	\$ 34,102

**(11) Share Repurchases**

In November 2007, the company's Board of Directors authorized the repurchase of \$35.0 million of the Company's common stock in open-market transactions, private transactions, tender offers, or other transactions. The repurchase authorization does not have a fixed expiration date. During the three months ended March 31, 2008, the Company repurchased 64,200 shares for \$2.6 million at an average price of \$40.56 per share under this plan. No shares were purchased in the three months ended December 31, 2007. As of March 31, 2008, \$32.4 million remains authorized and available for future purchases under the repurchase program.

**(12) Commitments and Contingencies**

*Litigation.* From time to time, the Company may become involved in various legal actions involving its products and technologies, including intellectual property disputes. The outcomes of these legal actions are not within the Company's complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, including injunctions barring the sale of products that are the subject of the lawsuit, which, if granted, could require significant expenditures or result in lost revenues. In accordance with SFAS No. 5,

Accounting for Contingencies, the Company records a liability in the consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. While it is not possible to predict the outcome for most of the actions discussed below and the Company believes that it has meritorious defenses against these matters, it is possible that costs associated with them could have a material adverse impact on the Company's consolidated earnings, financial condition or cash flows.

*Land Purchase Commitment.* In August 2007, the Company entered into an agreement to purchase an undeveloped parcel of land in Eden Prairie, Minnesota for approximately \$3.6 million (including a non-refundable deposit of \$100,000 paid to the seller at the time the purchase agreement was signed). The agreement requires that the Company complete the purchase on or before August 24, 2008 (the Closing Date). While it is the Company's current expectation to complete the purchase on or before the Closing Date, the Company will be required to pay the seller \$1.6 million if it fails to do so and will have no further rights to acquire the land. This \$1.6 million commitment is secured by a standby letter of credit as discussed in Note 4.

**(13) Subsequent Events**

In April 2008, the Company acquired a 286,000 square foot facility situated on 42 acres located in Birmingham, Alabama for \$12.2 million. The Company plans to remodel the existing facility to accommodate research and

development, clinical manufacturing and commercial manufacturing of drug delivery products for pharmaceutical and biotechnology customers. Total investment in this facility, including the \$12.2 million already paid, is expected to approximate \$30.0 million, and renovation and remodeling is expected to be completed over the next two years.

In May 2008, the Company invested an additional \$2.5 million in a subsidiary of Paragon (see Note 5 for additional information on previous investments in Paragon). The arrangement with the Paragon subsidiary called for the Company to invest the additional amount based upon successful completion of specified development milestones.

**Table of Contents****Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**  
**Overview**

SurModics is a leading provider of surface modification and drug delivery technologies to the healthcare industry. The Company is organized into three operating segments composed of seven technology-centered and industry-focused business units. The Drug Delivery operating segment consists of three business units: (1) the Drug Delivery business unit, which is responsible for technologies dedicated to site-specific delivery of drugs; (2) the Ophthalmology business unit, which is dedicated to the advancement of treatments for eye diseases, such as age-related macular degeneration (AMD) and diabetic macular edema (DME), two of the leading causes of blindness; and (3) the Brookwood Pharmaceuticals business unit, which provides proprietary polymer-based technologies to companies developing improved pharmaceutical products. The Hydrophilic and Other operating segment consists of three business units: (1) the Hydrophilic Technologies business unit, which focuses on enhancing medical devices with advanced lubricious coatings that facilitate their placement and maneuverability in the body; (2) the Regenerative Technologies business unit, which is developing platforms intended to augment or replace tissue/organ function (e.g., cell encapsulation applications), or to modify medical devices to facilitate tissue/organ recovery through natural repair mechanisms (e.g., hemo/biocompatible or prohealing coatings); and (3) the Orthopedics business unit, which is committed to innovative solutions for orthopedics patients using proven SurModics technologies, and creating new technology solutions to existing patient care gaps in the orthopedics field. The In Vitro operating segment consists of the In Vitro Technologies (formerly Diagnostics and Drug Discovery) business unit, which includes our genomics slide technologies, our stabilization products, antigens and substrates for immunoassay diagnostic tests, our *in vitro* diagnostic format technology and our synthetic ECM cell culture products.

Revenue in each of our operating segments is derived from three primary sources: (1) royalties and license fees from licensing our patented surface modification and drug delivery technologies and *in vitro* diagnostic formats to customers; the vast majority (typically in excess of 90%) of revenue in the royalties and license fees category is in the form of royalties; (2) the sale of reagent chemicals to licensees of our technologies, stabilization products, antigens and substrates to the diagnostics industry and coated glass slides to the genomics market; and (3) research and development fees generated on customer projects. Revenue should be expected to fluctuate from quarter to quarter depending on, among other factors: our customers' success in selling products incorporating our technologies; the timing of introductions of coated products by customers; the timing of introductions of products that compete with our customers' products; the number and activity level associated with customer development projects; the number and terms of new license agreements that are finalized; the value of reagent chemicals and other products sold to customers; and the timing of future acquisitions we complete, if any.

In June 2007, we signed a collaborative research and license agreement with Merck (the Merck Agreement) to pursue the joint development and commercialization of the I-vation sustained drug delivery system with triamcinolone acetonide and other products that combine Merck proprietary drug compounds with the I-vation system for the treatment of serious retinal diseases. Under the terms of our agreement with Merck, we received an up-front license fee of \$20 million and may receive up to an additional \$288 million in fees and development milestones associated with the successful product development and attainment of appropriate U.S. and EU regulatory approvals for these new combination products. We will also be paid for our activities in researching and developing these combination products. Additionally, under the terms of our agreement with Merck, we will be responsible for the exclusive manufacture and supply of clinical and commercial products. Once products licensed under the agreement are commercialized, we will also receive royalties on sales of such products.

Under EITF 00-21, we are amortizing the \$20 million license fee we received upon signing the agreement in June 2007, over the economic life of the technology we licensed to Merck, or 16 years. This accounting treatment, and the resulting amortization, also applies to current and future license fees and milestone payments. The commercial R&D fees that we are paid by Merck are also amortized over the same economic life. However, all of the costs of the R&D work we perform for Merck are expensed in the period performed. In addition, we recognize billings to Merck for reimbursed out-of-pocket expenses in the period incurred; accordingly such amounts are not amortized. As of March 31, 2008, the deferred revenue balance related to the Merck Agreement was \$24.9 million.

In July 2007, we acquired Brookwood Pharmaceuticals, Inc. ( Brookwood ), from Southern Research Institute, for \$40 million in cash at closing and up to an additional \$22 million in cash upon the successful achievement of specified milestones. In the second quarter of fiscal 2008 a milestone was achieved and \$2 million of additional purchase price was recorded as an increase to goodwill. Brookwood specializes in proprietary injectable microparticles and implants to provide sustained delivery of drugs being developed by leading pharmaceutical, biotechnology and medical device clients as well as emerging companies. This acquisition is expected to help us broaden our technology offerings to our customers, diversify the range of markets in which we participate, expand our customer base, and enhance our pipeline of potential revenue generating opportunities.

In August 2007, we acquired BioFX Laboratories, Inc. ( BioFX ), a provider of substrates to the *in vitro* diagnostics industry, for \$11.3 million in cash at closing and up to an additional \$11.4 million in cash upon the successful achievement of specified revenue targets. In the first quarter of fiscal 2008 a milestone was achieved and \$1.1 million of additional purchase

**Table of Contents**

price was recorded as an increase to goodwill. BioFX is a leading manufacturer of substrates, a critical component of diagnostic test kits used to detect and signal that a certain reaction has taken place. We expect our acquisition of BioFX to broaden our product portfolio in the *in vitro* diagnostics market.

The operating results for the Brookwood and BioFX businesses are included in the consolidated results of operations from the dates of acquisition.

For financial accounting and reporting purposes, we treat our three operating segments as one reportable segment. We made this determination because a significant percentage of our employees provide support services (including research and development) to each operating segment; technology and products from each operating segment are marketed to the same or similar customers; each operating segment uses the same sales and marketing resources; and each operating segment operates in the same regulatory environment.

**Critical Accounting Policies**

Critical accounting policies are those policies that require the application of management's most challenging subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Critical accounting policies involve judgments and uncertainties that are sufficiently sensitive to result in materially different results under different assumptions and conditions. For a detailed description of our critical accounting policies, see the notes to the financial statements included in our Annual Report on Form 10-K for the year ended September 30, 2007.

**Results of Operations**

	Three Months Ended March 31,		\$ Increase	% Increase
	2008	2007		
<i>(Dollars in thousands)</i>				
Revenue:				
Drug Delivery	\$ 11,955	\$ 6,205	\$ 5,750	93%
Hydrophilic and Other	8,261	6,546	1,715	26%
In Vitro	5,491	4,611	880	19%
Total revenue	\$ 25,707	\$ 17,362	\$ 8,345	48%

**Revenue.** Second quarter revenue was \$25.7 million, an increase of \$8.3 million or 48%, compared with the second quarter of fiscal 2007. Revenue included \$5.2 million from the acquisition of Brookwood and \$1.1 million from the acquisition of BioFX, which were completed in the fourth quarter of fiscal 2007. All three operating segments generated revenue growth, as detailed in the table above and further explained in the narrative below.

*Drug Delivery.* Revenue in the Drug Delivery segment was \$12.0 million in the second quarter of fiscal 2008, a 93% increase compared with \$6.2 million in the prior-year period. The increase in total revenue reflects a significant increase in research and development revenue from drug delivery and ophthalmology customers. Our Brookwood business unit generated \$5.2 million of revenue in the second quarter, whereas prior period results do not include any revenue from Brookwood. Excluding the contribution from Brookwood in the second quarter, Drug Delivery revenue increased 9% compared with the prior-year period.

Drug Delivery derives a substantial amount of revenue from royalties and license fees and product sales attributable to Cordis Corporation, a Johnson & Johnson company, on its CYPHER<sup>®</sup> Sirolimus-eluting Coronary Stent. The CYPHER<sup>®</sup> stent incorporates a proprietary SurModics polymer coating that delivers a therapeutic drug designed to reduce the occurrence of restenosis in coronary artery lesions.

Drug Delivery royalties and license fees decreased 3%, as increased royalties and license fees from ophthalmology and drug delivery customers nearly offset a 25% decrease in royalty revenue from Cordis as a result of lower CYPHER<sup>®</sup> sales.

Drug Delivery generated total revenue of \$1.1 million from Merck royalties, license fees and research and development activities during the three-month period ended March 31, 2008. In accordance with accounting for

arrangements with multiple elements, we are amortizing the payments received from Merck over the estimated 16 year economic life of the technology we licensed to Merck.

The CYPHER<sup>®</sup> stent, from which we derive a substantial amount of our Drug Delivery revenue, faces continuing competition from Boston Scientific Corporation's Taxus<sup>®</sup> drug-eluting stent and Medtronic's Endeavor<sup>®</sup> drug-eluting stent, which are sold domestically and internationally, and stents from Abbott Vascular and others sold outside the U.S. In addition,

**Table of Contents**

a drug-eluting stent from Abbott is expected to be approved in the U.S. within the next year. These stents compete or will compete directly with the CYPHER<sup>®</sup> stent. The Company also receives a royalty on the Medtronic Endeavor<sup>®</sup> drug-eluting stent, but the associated royalty revenue is reflected in the Hydrophilic and Other segment. In addition to competition among the various players, the total size of the drug-eluting stent market has decreased significantly in the past eighteen months as a result of concerns about product safety, mostly related to potential clotting associated with stents. Therefore, future royalty and reagent sales revenue could decrease due to lower CYPHER<sup>®</sup> stent sales as a result of the overall market contraction and the ongoing and expected future competition. We anticipate that quarterly royalty revenue from the CYPHER<sup>®</sup> stent may be volatile throughout fiscal 2008 and beyond as the various marketers of drug-eluting stents continue competing in the marketplace and as others enter the marketplace. Management expects royalties from the CYPHER<sup>®</sup> stent to continue to constitute a substantial portion of our revenue in fiscal 2008. However, whether and the extent to which royalties from the CYPHER<sup>®</sup> stent continue to constitute a significant source of revenue is subject to a number of risks, including intellectual property litigation generally, and specifically the damages, settlements and mutual agreements that may result from various infringement suits between Boston Scientific and Cordis in which each has been found to have violated certain intellectual property rights of the other.

The inclusion of revenue from our Brookwood business unit in Drug Delivery will also impact the overall revenue and mix in fiscal 2008, as a substantial majority of Brookwood revenue is comprised of research and development fees.

*Hydrophilic and Other.* Hydrophilic and Other revenue was \$8.3 million in the second quarter of fiscal 2008, an increase of 26% compared with \$6.5 million in the prior-year period, primarily as a result of 34% growth in royalties and license fees. This increase primarily reflects the Company's growing portfolio of licensed customers. In contrast to our Drug Delivery segment, where a significant percentage of revenue is attributable to Cordis, there are several dozen licensees and an even larger number of coated products generating royalties in this segment. The growth in royalties principally reflects increased sales of coated products already on the market, and to a lesser extent newly introduced licensed products. We believe that revenue will likely continue to increase for the remainder of fiscal 2008; however, the rate of growth will depend upon the timing and market success of our customers' newly released products, as well as the sales of existing products.

*In Vitro.* Revenue in the In Vitro segment was \$5.5 million in the second quarter of 2008, an increase of 19% compared with \$4.6 million in the prior-year period. The increase was attributable to increased product sales, mostly as a result of the addition of \$1.1 million of BioFX products sold during the quarter. The increase was partially offset by a decrease in royalties and license fees. Prior-year results do not include sales of BioFX products, because the acquisition of BioFX was completed in the fourth quarter of fiscal 2007. In Vitro segment royalties and license fees decreased principally because of lower underlying sales of licensed products in the second quarter of fiscal 2008. We anticipate continued growth in product sales for the remainder of fiscal 2008 reflecting particularly the addition of BioFX products, but the rate of growth will depend on the success of certain product launches. Royalties and license fees likely will not increase. In Vitro derives a significant percentage of its revenue from GE Healthcare and Abbott Laboratories. Royalty revenue generated under our diagnostic format patent license agreement with Abbott Laboratories (the Abbott Agreement) is expected to decline significantly following the expiration of the licensed patents in December 2008. Consistent with our revenue recognition practices, royalty revenue is recognized as licensees report it to us, which typically occurs on a quarter lag basis. Accordingly, we expect royalties generated under the Abbott Agreement to extend into the second quarter of fiscal 2009.

**Product costs.** Product costs were \$2.2 million in the second quarter of fiscal 2008, compared with \$1.1 million in the prior-year period. The \$1.1 million increase in product costs reflects principally the addition of product sales from BioFX and Brookwood and to a lesser extent a changing product mix. Overall product margins averaged 54%, compared with 68% reported last year. The decrease in product margins reflects the changing mix of products sold in the period. In particular, some of our stabilization and antigen products, genomics slides and Brookwood polymer products carry lower margins than our reagent products. We anticipate that product margins will continue to be lower on a year-over-year basis throughout fiscal 2008 when compared to prior-year results, principally as a result of revenue mix.

**Research and development expenses.** Research and development expenses were \$10.4 million for the second quarter, an increase of 81% compared with \$5.7 million in the prior-year period. The increase principally reflects the addition of Brookwood and BioFX to our operations, which together incurred total research and development expenses of \$3.5 million in the quarter. In addition, compensation expenses have increased as we have added personnel to support customer projects and internal development projects. Our research and development headcount has increased by six and eleven employees compared with December 31 and March 31, 2007, respectively, not including the addition of 53 research and development employees related to our Brookwood and BioFX acquisitions. Also contributing to the increase were a \$0.3 million increase in stock-based compensation, higher costs related to our internal development projects and \$0.4 million of out-of-pocket expenses in connection with our Merck projects, for which we are reimbursed. Research and development expenses are expected to continue to increase for the remainder of fiscal 2008, reflecting the addition of Brookwood and BioFX to our operations, and our continued expansion of the research and development organization. Research and development expenses for our Brookwood business unit, in particular, are a higher percentage of that unit's total revenues than for our other business units.

**Table of Contents**

**Selling, general and administrative expenses.** Selling, general and administrative ( SG&A ) expenses were \$6.0 million for the three-month period ended March 31, 2008, an increase of \$3.5 million compared with the prior-year period. The increase principally reflects the addition of Brookwood and BioFX to our operations, which comprised \$1.2 million of SG&A expenses. Our stock-based compensation expenses increased \$1.6 million this quarter principally as a result of recent transitions on our Board of Directors. We expect SG&A expenses to remain approximately at current levels for the remainder of fiscal 2008, reflecting the addition of Brookwood and BioFX to our operations, and continued expansion of our organization to support our anticipated growth.

**Other income, net.** Other income was \$1.2 million in the second quarter of fiscal 2008, consistent with the prior-year period. Income from investments was \$1.1 million, compared with \$1.2 million in the prior-year period. The decrease principally reflects lower yields from our investment portfolio. Offsetting the decrease in investment income was \$0.1 million in other income.

**Income tax expense.** The income tax provision was \$3.3 million in the second quarter of fiscal 2008, compared with \$3.6 million in the prior-year period. The effective tax rate was 38.9%, compared with 38.7% in the prior-year period. This increase is primarily attributable to tax reserve increases for state tax contingencies.

	<b>Six Months Ended March 31,</b>			
	<b>2008</b>	<b>2007</b>	<b>\$ Increase</b>	<b>% Increase</b>
<i>(Dollars in thousands)</i>				
Revenue:				
Drug Delivery	\$ 22,723	\$ 12,834	\$ 9,889	77%
Hydrophilic and Other	15,815	11,823	3,992	34%
In Vitro	10,998	9,445	1,553	16%
Total revenue	\$ 49,536	\$ 34,102	\$ 15,434	45%

**Revenue.** Total revenue was \$49.5 million for the first six months of fiscal 2008, an increase of \$15.4 or 45%, compared with the same period of fiscal 2007. Revenue included \$11.7 million from the acquisitions of Brookwood and BioFX businesses, which were completed in the fourth quarter of fiscal 2007. All three operating segments generated revenue growth, as detailed in the table above and further explained in the narrative below.

*Drug Delivery.* Drug Delivery revenue increased 77% to \$22.7 million for the first half of fiscal 2008 compared with \$12.8 million for the same period last year. The increase in total revenue reflects a significant increase in research and development revenue from drug delivery and ophthalmology customers, offset partially by lower royalties and license fees. Our Brookwood business unit generated \$9.4 million of revenue in the first six months of fiscal 2008. Prior-period results do not include any revenue from Brookwood, as the acquisition was completed in the fourth quarter of 2007. The decrease in Drug Delivery royalties and license fees principally reflects decreased royalty revenue from Cordis as a result of lower CYPHER® sales. Substantially offsetting the decrease attributable to CYPHER® was an increase in royalties and license fees from other drug delivery and ophthalmology customers, including Merck.

*Hydrophilic and Other.* Hydrophilic and Other revenue increased 34% to \$15.8 million compared with \$11.8 million for the same period last year. The growth was driven principally by increased royalties and license fees as the company continues to grow its licensed customer base.

*In Vitro.* In Vitro revenue increased 16% to \$11.0 million compared with \$9.4 million for the same period last year. The increase was attributable to increased product sales, mostly as a result of the addition of \$2.2 million of BioFX products sold during the period. The increase was partially offset by a decrease in royalties and license fees. Prior-period results do not include sales of BioFX products, because the acquisition of BioFX was completed in the fourth quarter of fiscal 2007. In Vitro segment royalties and license fees decreased principally because the prior-year results included a settlement related to past due royalties; there was no such settlement in the first half of fiscal 2008.

**Product costs.** Product costs were \$4.1 million for the six months ended March 31, 2008, an 89% increase from \$2.2 million for the same period last year. Overall product margins averaged 58% compared with 64% for the comparable period last year. The margin decrease was primarily attributable to a lower mix of reagent sales which carry higher gross margins than our other products.

**Research and development expenses.** Research and development expenses were \$19.9 million for the first six months of fiscal 2008, an increase of 82% compared with \$10.9 million for the same period of fiscal 2007. The increase principally reflects the addition of Brookwood and BioFX to our operations, which together had total research and development expenses of \$6.5 million in the first six months of fiscal 2008. In addition, compensation expenses have increased as we have

**Table of Contents**

added personnel to support customer projects and internal development projects. Our research and development headcount has increased by eight and eleven compared with September 30 and March 31, 2007, respectively, not including the addition of 53 research and development employees from our Brookwood and BioFX acquisitions. We have also incurred higher costs related to our internal development projects, and \$1.0 million of out-of-pocket expenses were incurred in connection with our Merck projects, for which we are reimbursed.

**Selling, general and administrative expenses.** SG&A expenses were \$10.8 million for the first six months of fiscal 2008, an increase of \$6.0 million compared with the prior-year period. The increase principally reflects the addition of Brookwood and BioFX to our operations, as they incurred \$2.3 million of SG&A expenses. Our stock-based compensation expenses were \$2.0 million higher for the first six months of fiscal 2008 mainly associated with recent transitions on our Board of Directors.

**Other income, net.** Other income was \$2.9 million for the first six months of fiscal 2008 compared with income of \$2.5 million in the same period of fiscal 2007. Income from investments was \$2.0 million, compared with \$2.5 million in the prior-year period. The decrease principally reflects a decrease in investable cash and lower yields in our investment portfolio. Offsetting the decrease in investment income was \$0.9 million in other income.

**Income tax expense.** The income tax provision was \$6.9 million for the first six months of fiscal 2008, compared with \$7.0 million for the same period in fiscal 2007. The effective tax rate for the first six months of fiscal 2008 was 39.1%, compared with 37.6% for the same period last year. The increase in the effective tax rate principally reflects an increase in state tax contingency reserves in fiscal 2008 and to a release of federal tax reserves in fiscal 2007.

**Liquidity and Capital Resources**

As of March 31, 2008, the Company had working capital of \$48.6 million, of which \$37.8 million consisted of cash, cash equivalents and short-term investments. Working capital increased \$20.6 million from the September 30, 2007 level driven principally by cash flow from operations, changes in income tax assets and liabilities, and the collection of \$5.8 million of notes receivable. Our cash, cash equivalents and short-term and long-term investments totaled \$80.9 million at March 31, 2008, an increase of \$10.7 million from \$70.2 million as of September 30, 2007. The Company's investments principally consist of U.S. government and government agency obligations and investment grade, interest-bearing corporate debt securities with varying maturity dates, the majority of which are five years or less. The Company's policy requires that no more than 5% of investments be held in any one credit issue, excluding U.S. government and government agency obligations. The primary investment objective of the portfolio is to provide for the safety of principal and appropriate liquidity while meeting or exceeding a benchmark (Merrill Lynch 1-3 Year Government-Corporate Index) total rate of return. Management plans to continue to direct its investment advisors to manage the Company's investments primarily for the safety of principal for the foreseeable future as it assesses other investment opportunities and uses of its investments.

We had cash flows from operating activities of approximately \$8.9 million in the six months ended March 31, 2008, compared with \$16.5 million the six months ended March 31, 2007. The decrease compared with prior-year results primarily reflects timing of income tax payments and accounts receivable increasing in the six months, rather than being a source of cash as it was in the prior-year period.

In November 2007, our Board of Directors authorized the repurchase of up to \$35 million of the Company's common stock in open-market transactions, private transactions, tender offers, or other transactions. The repurchase authorization does not have a fixed expiration date. We entered into a Rule 10b5-1 agreement in January 2008 and during the second quarter of fiscal 2008 purchased 64,200 shares of common stock for \$2.6 million at an average price of \$40.52 per share. Under the current authorization the Company has \$32.4 million remaining available for authorized share repurchases as of March 31, 2008.

As of March 31, 2008, we had approximately \$236,000 of debt outstanding in connection with our Brookwood subsidiary. We do not have any material credit agreements established, and we believe that our existing capital resources will be adequate to fund our operations and material commitments into the foreseeable future. Our remaining anticipated liquidity needs for fiscal 2008 include but are not limited to the following: milestone payments associated with prior-year business acquisitions of approximately \$3 million; capital expenditures related to the recently acquired Alabama facility in the range of \$13 million to \$18 million (including the \$12.2 million paid in April 2008) and related to our Minnesota facilities in the range of \$4 million to \$8 million; and any amounts

associated with the repurchase of common stock under the authorization discussed above.

As of March 31, 2008, the Company did not have any off-balance sheet arrangements with any unconsolidated entities.

**Table of Contents****Forward-Looking Statements**

Certain statements contained in this report and other written and oral statements made from time to time by the Company do not relate strictly to historical or current facts. As such, they are considered forward-looking statements that provide current expectations or forecasts of future events. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements can be identified by the use of terminology such as anticipate, believe, could, estimate, expect, forecast, intend, may, project, will and similar words or expressions. Any statement that is not an historical fact, including estimates, projections, future trends and the outcome of events that have not yet occurred, are forward-looking statements. The Company's forward-looking statements generally relate to its growth strategy, financial results, product development programs, sales efforts, sufficiency of capital resources, and the impact of the Cordis agreement and other significant customer agreements. You should carefully consider forward-looking statements and understand that such statements involve a variety of risks and uncertainties, known and unknown, and may be affected by inaccurate assumptions. Consequently, no forward-looking statement can be guaranteed and actual results may vary materially. The Company undertakes no obligation to update any forward-looking statement.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the Company's forward-looking statements, such factors include, among others: (i) the Company's significant dependence upon Cordis, which causes our financial results and stock price to be subject to factors affecting Cordis and its Cypher stent program, including among others, the rate of market penetration by Cordis, the timing of market introduction of competing products, product safety or efficacy concerns and intellectual property litigation generally and specifically the litigation involving Boston Scientific Scimed, Inc. and Cordis in the U.S. District Court for the District of Delaware in which each was reported in June and July 2005 to have been found to have infringed the patent rights of the other; (ii) frequent intellectual property litigation in the medical device industry that may directly or indirectly adversely affect our customers' ability to market their products incorporating our technologies; (iii) failure to obtain intellectual property rights protecting our proprietary technologies, or the expiration or loss of such rights, could have a material adverse effect on our business, financial condition and results of operations; (iv) healthcare reform efforts and reimbursement rates for medical device products that may adversely affect our customers' ability to cost effectively market and sell devices incorporating our technologies; (v) the Company's ability to attract new licensees and to enter into agreements for additional product applications with existing licensees, the willingness of potential licensees to sign license agreements under the terms offered by the Company, and the Company's ability to maintain satisfactory relationships with its licensees; (vi) the Company's ability to increase the number of market segments and applications that use its coating technologies through its sales and marketing and research and development efforts; (vii) the Company's ability to facilitate through strategic investment and research and development support the creation of new medical device market segments and applications that incorporate its coating technologies; (viii) market acceptance of products sold by customers incorporating our technologies and the timing of new product introductions by licensees; (ix) market acceptance of products sold by customers' competitors and the timing and pricing of new product introductions by customers' competitors; (x) the difficulties and uncertainties associated with the lengthy and costly new product development and foreign and domestic regulatory approval processes, such as delays, difficulties or failures in achieving acceptable clinical results or obtaining foreign or FDA marketing clearances, which may result in lost market opportunities or postpone or preclude product commercialization by licensees; (xi) efficacy or safety concerns with respect to products marketed by us and our licensees, whether scientifically justified or not, that may lead to product recalls, withdrawals or declining sales; (xii) the ability to secure raw materials for reagents the Company sells; (xiii) the Company's ability to manage successfully clinical trials and related foreign and domestic regulatory processes for the I-vation intravitreal implant or other acquired products from InnoRx under development by the Company's ophthalmology division, whether delays, difficulties or failures in achieving acceptable clinical results or obtaining foreign or FDA marketing clearances postpone or preclude product commercialization of the intravitreal implant or other acquired products, and whether the intravitreal implant and any other acquired products remain viable commercial prospects; (xiv) product liability claims not covered by insurance; (xv) the development of new products or technologies by competitors, technological obsolescence and other changes in competitive factors; (xvi) the trend of consolidation in the medical

device industry, resulting in more significant, complex and long term contracts than in the past and potentially greater pricing pressures; (xvii) the Company's ability to identify suitable businesses to acquire or with whom to form strategic relationships to expand its technology development and commercialization, its ability to successfully integrate the operations of companies it may acquire from time to time (including Brookwood Pharmaceuticals, Inc., and BioFX Laboratories, Inc.) and its ability to create synergies from acquisitions and other strategic relationships; (xviii) difficulties in bringing our facilities into compliance with good manufacturing practices or other applicable regulatory standards may adversely impact our ability to manufacture and supply products, or perform other services for our customers; (xix) the Company's ability to successfully internally perform certain product development activities and governmental and regulatory compliance activities with respect to acquired technology, including InnoRx technology, which activities the Company has not previously undertaken in any significant manner; (xx) the Company's ability to successfully perform and earn milestone payments related to contractual milestone criteria in general and specifically the \$288 million in fees and development milestones in the Merck Agreement; (xxi) economic and other factors over which the Company has no control, including changes in inflation and consumer confidence; (xxii) acts of God or terrorism which impact the Company's personnel or facilities; and (xxiii) other factors described in the Risk Factors and other sections of SurModics' Annual Report on Form 10-K, which you are encouraged to read carefully. Many of these factors are outside the control and knowledge of the Company and could result in increased volatility in period-to-period results. Investors are advised not to place undue reliance upon the Company's forward-looking information and to consult any further disclosures by the Company on this subject in its filings with the Securities and Exchange Commission.

**Table of Contents**

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

The Company's investment policy requires investments with high credit quality issuers and limits the amount of credit exposure to any one issuer. The Company's investments principally consist of U.S. government and government agency obligations and investment-grade, interest-bearing corporate debt securities with varying maturity dates, the majority of which are five years or less. Because of the credit criteria of the Company's investment policy, the primary market risk associated with these investments is interest rate risk. The Company does not use derivative financial instruments to manage interest rate risk or to speculate on future changes in interest rates. A one percentage point increase in interest rates would result in an approximate \$894,000 decrease in the fair value of the Company's available-for-sale securities as of March 31, 2008, but no material impact on the results of operations or cash flows. Management believes that a reasonable change in raw material prices would not have a material impact on future earnings or cash flows because the Company's inventory exposure is not material.

Although we conduct business in foreign countries, our international operations consist primarily of sales of reagent and stabilization chemicals. Additionally, all sales transactions are denominated in U.S. dollars. Accordingly, we do not expect to be subject to material foreign currency risk with respect to future costs or cash flows from our foreign sales. To date, we have not entered into any foreign currency forward exchange contracts or other derivative financial instruments to hedge the effects of adverse fluctuations in foreign currency exchange.

**Item 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

As of the end of the period covered by this report, the Company conducted an evaluation under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer regarding the effectiveness of the design and operation of the Company's disclosure controls and procedures, as defined in to Rule 13a-15(e) of the Securities Exchange Act of 1934 (the Exchange Act), pursuant to Rule 13a-15(b) of the Exchange Act. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective as of such time.

**Changes in Internal Controls**

There were no changes in the Company's internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

**Table of Contents****PART II OTHER INFORMATION****Item 1. Legal Proceedings.**

There have been no material developments in the legal proceedings previously disclosed in the Company's Form 10-K for the fiscal year ended September 30, 2007.

**Item 1A. Risk Factors.**

There have been no material changes from risk factors as previously disclosed in the Company's Form 10-K for the fiscal year ended September 30, 2007 in response to Item 1A to Part I of Form 10-K.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.****(c) Issuer Purchases of Equity Securities**

The following table presents information with respect to purchases of common stock of the Company made during the three months ended March 31, 2008, by the Company or on behalf of the Company or any affiliated purchaser of the Company, as defined in Rule 10b-18(a)(3) under the Exchange Act.

Period	(a) Total Number of Shares Purchased(1)	(b) Average Price Paid Per Share	(c) Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	(d) Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs(2)
1/01/08 1/31/08	0	NA	NA	NA
2/01/08 2/29/08	0	NA	NA	NA
3/01/08 3/31/08	67,390	\$40.50	64,200	\$32,398,599
Total	67,390	\$40.50	64,200	\$32,398,599

(1) The purchases in this column included shares repurchased as part of our publicly announced program and in addition include 3,190 shares that were repurchased by the Company to satisfy tax withholding obligations in connection with so-called stock

swap exercises related to the vesting of restricted stock awards.

- (2) On November 15, 2007, our Board of Directors announced the authorization of the repurchase of \$35 million of its outstanding common stock. As of March 31, 2008, we have repurchased 64,200 shares at an average price of \$40.52 per share. Under the current authorization the Company has \$32.4 million available for authorized share repurchases as of March 31, 2008, and such authorization has no expiration date.

**Item 3. Defaults Upon Senior Securities.**

Not Applicable.

**Item 4. Submission of Matters to a Vote of Security Holders.**

The information disclosed under Part II Item 4 of the Company's Quarterly Report on Form 10-Q for the period ended December 31, 2007 is incorporated herein by reference.

**Item 5. Other Information.**

Not Applicable.

**Table of Contents**

**Item 6. Exhibits.**

<b>Exhibit</b>	<b>Description</b>
3.1	Restated Articles of Incorporation, as amended incorporated by reference to Exhibit 3.1 of the Company's Quarterly Report on Form 10-QSB for the quarter ended December 31, 1999, SEC File No. 0-23837
3.2	Restated Bylaws incorporated by reference to Exhibit 3.2 of the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2007, SEC File No. 0-23837
10.1	Real Estate Purchase Agreement between Brookwood Pharmaceuticals, Inc., and Belk, Inc., dated March 11, 2008**
31.1	Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002**
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002**
32.1	Certification of Chief Executive Officer Pursuant to Section 906 of Sarbanes-Oxley Act of 2002**
32.2	Certification of Chief Financial Officer Pursuant to Section 906 of Sarbanes-Oxley Act of 2002**

\*\* Filed herewith.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SurModics, Inc.**

Date: May 9, 2008

By: /s/ Philip D. Ankeny  
Philip D. Ankeny  
Senior Vice President and Chief  
Financial Officer  
(duly authorized officer and principal  
financial officer)

20

---

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
EXHIBIT INDEX TO FORM 10-Q  
For the Quarter Ended March 31, 2008  
SURMODICS, INC.**

<b>Exhibit</b>	<b>Description</b>
3.1	Restated Articles of Incorporation, as amended incorporated by reference to Exhibit 3.1 of the Company's Quarterly Report on Form 10-QSB for the quarter ended December 31, 1999, SEC File No. 0-23837
3.2	Restated Bylaws incorporated by reference to Exhibit 3.2 of the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2007, SEC File No. 0-23837
10.1	Real Estate Purchase Agreement between Brookwood Pharmaceuticals, Inc., and Belk, Inc., dated March 11, 2008**
31.2	Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002**
32.1	Certification of Chief Executive Officer Pursuant to Section 906 of Sarbanes-Oxley Act of 2002**
32.2	Certification of Chief Financial Officer Pursuant to Section 906 of Sarbanes-Oxley Act of 2002**

\*\* Filed herewith.